



Building Sustainable Access at Scale



Our continuous work to advance more sustainable operations and responsible practices serves as a strong foundation to make further progress on our mission, strategy and overall business model, collectively driving our focus on increasing access to medicine and creating long-term value for our key stakeholders.

2023 HIGHLIGHTS

Access and Global Health

Supplied high-quality medicines to **~1 billion** patients around the world¹

Sold more than **80 billion** doses of medicine across more than **165 countries and territories**, reaching **>90% of low- and lower-middle-income countries (LMICs)**

More than 250 medicines on the World Health Organization (WHO) Essential Medicines List to help address priority healthcare needs as defined by the WHO

59 products on the WHO Prequalification List, which allows for U.N. and other multilateral donor procurement, as well as accelerated registration processes in LMICs

Environment



Named to USA Today's inaugural list of **America's Climate Leaders 2023** for companies that have demonstrated the greatest reduction in emissions intensity

Our manufacturing for all dosages of the antibiotic Ciprofloxacin at our facility in Aurangabad, India, became the first at Viatriis and in India to receive **British Standards Institute (BSI) Certification** under the **Antibiotic Manufacturing Standard**

Our Commitment to Access and Health

Access is fundamental to our mission. It is not an initiative; it is our business model. It begins with our ability to sustainably deliver quality medicines at scale to people, regardless of geography or circumstance. With an extensive portfolio of medicines to address nearly every health need, a one-of-a-kind global supply chain designed to reach more people with health solutions when and where they need them, and the scientific expertise to address some of the world's most enduring health challenges, access is central to everything we do.

In 2023, we made progress on our goals to provide access to antiretrovirals and promote healthcare professional education and outreach.

- Provided treatments for approximately 8.6 million patients, including more than 670,000 children living with HIV/AIDS. Since 2022, we have provided treatments for nearly 17 million adults and children.
- Nearly 5,000 new users signed on to the NCD Academy in 2023, for a total of more than 24,000 accounts created, representing approximately 60.5 million patients impact to date.³

Our People



We have approximately **38,000 colleagues²** across almost 70 countries



97% participation of all colleagues globally engaged on diversity, equity and inclusion (DEI) learning

Community

Donated more than 300 million doses of medicines for humanitarian needs through our partners around the world and **funds for humanitarian relief** to global partners via corporate philanthropy donations

Recognitions



Our People

Behind every Viatris achievement are members of our global workforce, dedicated to advancing our mission by leveraging their unique experiences, skills and abilities. Viatris is committed to providing opportunities for our people to achieve their full potential and collectively advance our shared goal of improving healthcare around the world. We do this through programs for our colleagues' wellbeing, promoting an inclusive culture, providing competitive total rewards, and fostering career growth and professional development.

In 2023, we launched Elevate, our new wellbeing program for all colleagues, centered around three principles: Health, Purpose and Growth.

Environmental Stewardship

Working to ensure stable access to high-quality medicines depends upon continuously working to further advance responsible and sustainable operations.

Our work as environmental stewards is governed by our global Environmental, Health and Safety (EHS) management system, which serves to help ensure compliance with both local regulations

and global company policies and requirements, while also fostering a culture of ongoing improvement.

- Our reduction targets for scope 1 and 2, and scope 3 greenhouse gas emissions have been approved and validated by the SBTi. We are making progress and believe our current strategy is on track to deliver on our reduction target by 2030.
- We performed six water risk assessments in 2023, bringing our total since 2022 to 11 water risk assessments completed.
- Thirteen sites achieved zero-waste landfill in 2023, with six additional sites at less than 5% of waste going to landfill.

Community

Making the world a better place starts at home. At Viatris, that means working to support and promote health, education and community wellbeing in the diverse places we call home around the world. In some places, support may mean helping communities recover from severe weather events or responding to medical needs of families displaced by war or political crises. In each case, it's the power of partnerships that helps us to reach those in need.



Viatris' Key Sustainability Areas

At the center of everything we do, Viatris works to create sustainable access to medicine to achieve better patient outcomes and advance global public health. We focus on key sustainability topics, all of which we pursue simultaneously to help drive our mission.

These key topics encompass four broad areas:

- **Reliable Supply and High-Quality Medicine:** manufacturing and distribution, including our supply chain and regulatory impact;
- **Our People:** managing talent, engaging employees and promoting workplace health and safety and diversity and inclusion;
- **Environmental Impact:** minimizing environmental impact – from climate change and energy to water and waste management; and
- **Governance and Ethical Practices:** managing inherent risks and encouraging opportunities and business ethics.



For more information, read the [Viatris 2023 Sustainability Report](#).

¹The number of patients served is an estimate calculated using internal sales data (global volume of doses sold in 2022 in all markets as aligned with IQVIA standard units), divided by estimated per patient usage, which is based on treatment dose, treatment duration, and treatment adherence as estimated by Viatris Medical Affairs based on approved label indication and instructions for use, current international guideline recommendations, and common usage in clinical practice. Patients using multiple Viatris medicines may be counted as multiple patients. Certain adjustments were applied in consideration of announced divestitures and to account for acceptable alternatives to the patient usage factors noted above, and rounded to the nearest hundred million. Estimates may be subject to reassessment.

²Excludes contingent workers.

³Patient reach calculated by multiplying the number of HCP learners by the average number of patients treated, as self-reported by HCP learners upon registering for NCD Academy. Patient reach includes unique patients as well as repeat patient encounters.



Viatris.com



LinkedIn



@ViatrisInc



@ViatrisInc



YouTube



Listen Well Podcast